Antibiotics Market by Action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, Others), Drug Class, Spectrum of Activity, Route of Administration, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026
Published On: July 2019
 
Report ID:396103
 
Category: Pharmaceutical
 
Pages: 250




Global antibiotics market is expected to reach to USD 67.25 Billion by 2026 at a CAGR of 4.7% during the forecast period 2019-2026. Rising incidences of infectious diseases and increasing collaborative development efforts are the two factors affecting the demand of the market.

Market Overview:

Antibiotics, also known as antibacterial or antimicrobials, are defined as a group of medicines used in the treatment of infections caused by germs-bacteria and certain parasites by inhibiting the growth of microorganisms or killing them. After the discovery of the antibiotic penicillin in 1920, various antibiotic compounds have been used to treat several bacterial infections. It combats bacterial infections and occasionally protozoan infections. In addition, they are used to cure several diseases such as strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, ear infections, and others.

Report Description:

  • The base year for the study has been considered 2018, historic year 2017 and 2017, the forecast period considered is from 2019 to 2026. The antibiotics market is analysed on the basis of value (USD Billion) and volume (Thousand Units).
  • The study delivers a comprehensive analysis of global antibiotics market by action, drug class, spectrum of activity, route of administration and regions.
  • The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
  • Porter’s Five Forces model is used in order to recognize the competitive scenario in the global antibiotics market. This report incorporates the industry analysis which is focused on providing an extensive view of the antibiotics market.
  • The study also includes attractiveness analysis of action, drug class, spectrum of activity, route of administration and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
  • The report provides company profile of the key players operating in the antibiotics market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
  • The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Market Dynamics:

Drivers:

  • Development of better and improved products
  • Rising incidences of infectious diseases
  • Increasing collaborative development efforts

Restraints:

  • Uncertain regulatory policies
  • High R & D cost

Opportunities:

  • Evolution of advanced molecules and novel combination therapies to treat antibiotic-resistant microbial infections is likely to spur market growth.

Challenges:                                                                                                                           

  • Growing resistance to antibiotics

Global Antibiotics Market Key Findings:

All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment.

Segmentation Analysis:

The antibiotics market is segmented on the basis of action, drug class, spectrum of activity and route of administration.

  • The action segment is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors and mycolic acid inhibitors. RNA synthesis inhibitors segment is growing with the highest CAGR of 6.1% in the forecast period. Adoption of several antiviral drugs inhibiting transcription and reverse transcription process are expected to promote the growth of the market.
  • The drug class segment is segmented into cephalosporin, penicillin, fluoroquinolone, macrolides, carbapenem, aminoglycosides, sulfonamides, and other. The other antibiotics segment is anticipated to expand at the highest CAGR of 7.6% during the forecast year. The other antibiotics segment comprises of tetracyclines, imidazoles, lincosamides, and monoclonal antibodies. The development of monoclonal antibodies for individuals that have developed antibiotic-resistance is a vital component for the growth of this segment.
  • The spectrum of activity segment is segmented into broad-spectrum antibiotic and narrow-spectrum antibiotic. The broad-spectrum antibiotic segment is dominating the market with the highest share of 59.90% in 2018. Broad-spectrum antibiotics act against a wide range of diseases, which in turn helps to combat antimicrobial resistance.
  • The route of administration segment is segmented into oral, intravenous and others. The intravenous segment is dominating the market and valued around USD 23.77 Billion in 2018 due to rise in incidence of severe infections. Moreover, as intravenous antibiotics are administered in higher concentrations, they reach the tissues faster as compared to oral antibiotics.

Regional Segmentation Analysis:

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region dominated the global antibiotics market with USD 19.24 Billion in 2018 where as the Asia Pacific region is growing rapidly in the market.

  • North America region is dominating the market owing to the increased use of antibiotics. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, due to decrease in the unemployment rate.
  • Asia Pacific is anticipated to grow rapidly owing to large population base, increasing instances of infectious diseases, regulation reforms, and greater usage of generic medicines.

Global Antibiotics Market Competitive Analysis:

Key players in the antibiotics market are Pfizer, Inc; Janssen Pharmaceuticals; Abbott laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly & Company, and Astellas Pharma, Inc, Allergan Plc, F.Hoffmann-La Roche Ltd, Merck & Co. Inc., Mylan N.V., Sanofi, Teva Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, among many others. For instance, In August 2016, Pfizer entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infective business, mainly outside U.S.

*All our reports are customizable as per customer requirements

This study forecasts revenue and volume growth at global, regional, and country levels from 2016 to 2026. Fior Market Research has segmented the global antibiotics market on the basis of below mentioned segments:

Global Antibiotics Market, By Action:

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors

 Global Antibiotics Market, By Drug Class:

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides
  • Others

Global Antibiotics Market, By Spectrum of Activity:

  • Broad-spectrum Antibiotic
  • Narrow-spectrum Antibiotic

Global Antibiotics Market, By Route of Administration:

  • Oral
  • Intravenous
  • Others

Global Antibiotics Market, By Regions:

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Asia-Pacific
  • Japan
  • China
  • India
  • South America
  • Brazil
  • Middle East and Africa         
  • UAE
  • South Africa
  1. INTRODUCTION
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. RESEARCH SCOPE
    4. CURRENCY
  2. RESEARCH METHODOLOGY AND ASSUMPTIONS
  3. EXECUTIVE SUMMARY
  4. PREMIUM INSIGHTS
    1. TOP INVESTMENT POCKETS
      1. MARKET ATTRACTIVENESS ANALYSIS BY ACTION
      2. MARKET ATTRACTIVENESS ANALYSIS BY DRUG CLASS
      3. MARKET ATTRACTIVENESS ANALYSIS BY SPECTRUM OF ACTIVITY
      4. MARKET ATTRACTIVENESS ANALYSIS BY ROUTE OF ADMINISTRATION
      5. MARKET ATTRACTIVENESS ANALYSIS BY REGION
    2. PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRANTS
      2. THREAT OF SUBSTITUTES
      3. BARGAINING POWER OF SUPPLIERS
      4. BARGAINING POWER OF BUYERS
      5. INTENSITY OF COMPETITIVE RIVALRY
    3. PESTEL ANALYSIS
    4. INDUSTRY SWOT ANALYSIS
    5. INDUSTRY TRENDS
    6. MICRO AND MACRO FACTORS AFFECTING GLOBAL ADVANCED WOUND CARE
    7. PRICING ANALYSIS
      1. PRICING ASSUMPTIONS
      2. PRICE PROJECTIONS PER REGION
    8. MACRO-ECONOMIC FACTORS
      1. SUPPLY SIDE
      2. DEMAND SIDE
    9. TRADE MAP ANALYSIS (IMPORT-EXPORT DATA)
    10. COUNTRY LEVEL ANALYSIS
    11. PENETRATION & GROWTH PROSPECT MAPPING
    12. INDUSTRY VALUE CHAIN ANALYSIS
      1. RAW MATERIALS ANALYSIS
      2. SUPPLIER ANALYSIS
      3. END USER ANALYSIS
    13. CUSTOMERS/BUYERS BY REGIONS
  5. MARKET DYNAMICS
    1. MARKET EVALUATION
    2. DRIVERS
      1. DEVELOPMENT OF BETTER AND IMPROVED ACTION
      2. RISING INCIDENCES OF INFECTIOUS DISEASES
      3. INCREASING COLLABORATIVE DEVELOPMENT EFFORTS
    3. RESTRAINTS
      1. UNCERTAIN REGULATORY POLICIES
      2. HIGH R & D COST
    4. OPPORTUNITIES
      1. EVOLUTION OF ADVANCED MOLECULES AND NOVEL COMBINATION THERAPIES TO TREAT ANTIBIOTIC-RESISTANT MICROBIAL INFECTIONS IS LIKELY TO SPUR MARKET GROWTH.
    5. CHALLENGES
      1. GROWING RESISTANCE TO ANTIBIOTICS.
  6. GLOBAL ANTIBIOTICS MARKET ANALYSIS AND FORECAST, BY ACTION
    1. SEGMENT OVERVIEW
    2. CELL WALL SYNTHESIS INHIBITORS
    3. PROTEIN SYNTHESIS INHIBITORS
    4. DNA SYNTHESIS INHIBITORS
    5. RNA SYNTHESIS INHIBITORS
    6. MYCOLIC ACID INHIBITORS
  7. GLOBAL ANTIBIOTICS MARKET ANALYSIS AND FORECAST, BY DRUG CLASS
    1. SEGMENT OVERVIEW
    2. CEPHALOSPORIN
    3. PENICILLIN
    4. FLUOROQUINOLONE
    5. MACROLIDES
    6. CARBAPENEM
    7. AMINOGLYCOSIDES
    8. SULFONAMIDES
    9. OTHERS
  8. GLOBAL ANTIBIOTICS MARKET ANALYSIS AND FORECAST, BY SPECTRUM OF ACTIVITY
    1. SEGMENT OVERVIEW
    2. BROAD-SPECTRUM ANTIBIOTIC
    3. NARROW-SPECTRUM ANTIBIOTIC
  9. GLOBAL ANTIBIOTICS MARKET ANALYSIS AND FORECAST, BY DRUG CLASS
    1. SEGMENT OVERVIEW
    2. ORAL
    3. INTRAVENOUS
    4. OTHERS
  10. GLOBAL ANTIBIOTICS MARKET ANALYSIS AND FORECAST, BY REGIONAL ANALYSIS
    1. SEGMENT OVERVIEW
    2. NORTH AMERICA
      1. U.S.
      2. CANADA
      3. MEXICO
    3. EUROPE
      1. GERMANY
      2. FRANCE
      3. U.K.
      4. ITALY
      5. SPAIN
      6. REST OF EUROPE
    4. ASIA-PACIFIC
      1. JAPAN
      2. CHINA
      3. INDIA
      4. REST OF APAC
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF SA
    6. MIDDLE EAST AND AFRICA
      1. UAE
      2. SOUTH AFRICA
      3. REST OF MEA
  11. GLOBAL ANTIBIOTICS MARKET-COMPETITIVE LANDSCAPE
    1. OVERVIEW
    2. MARKET SHARE OF KEY PLAYERS IN THE ANTIBIOTICS MARKET
      1. GLOBAL COMPANY MARKET SHARE
      2. NORTH AMERICA COMPANY MARKET SHARE
      3. EUROPE COMPANY MARKET SHARE
      4. APAC COMPANY MARKET SHARE
    3. COMPETITIVE SITUATIONS AND TRENDS
      1. PRODUCT LAUNCHES AND DEVELOPMENTS
      2. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
      3. MERGERS & ACQUISITIONS
      4. EXPANSIONS
  12. COMPANY PROFILES
    1. PFIZER, INC.
      1. BUSINESS OVERVIEW
      2. COMPANY SNAPSHOT
      3. KEY FINANCIAL
        1. REVENUE ANALYSIS
        2. PRICE ANALYSIS
        3. COST ANALYSIS
        4. VOLUME ANALYSIS
        5. MARGIN ANALYSIS
        6. COMPANY SEGMENT ANALYSIS
      4. COMPANY PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
      6. SWOT ANALYSIS
    2. JANSSEN PHARMACEUTICALS
    3. ABBOTT LABORATORIES
    4. GLAXOSMITHKLINE PLC
    5. SANOFI S.A.
    6. NOVARTIS AG
    7. BAYER AG
    8. BRISTOL MYERS SQUIBB COMPANY
    9. ELI LILLY & COMPANY
    10. ASTELLAS PHARMA, INC.
    11. ALLERGAN PLC
    12. F.HOFFMANN-LA ROCHE LTD.
    13. MYLAN N.V.
    14. SANOFI.
    15. TEVA PHARMACEUTICAL INDUSTRIES LTD.
    16. AUROBINDO PHARMA.
    17. LUPIN PHARMACEUTICALS.
    18. SUN PHARMACEUTICAL
    19. SHIONOGI.
    20. MERCK & CO. INC.

LIST OF TABLE

  1. GLOBAL ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  2. GLOBAL CELL WALL SYNTHESIS INHIBITORS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  3. GLOBAL PROTEIN SYNTHESIS INHIBITORS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  4. GLOBAL DNA SYNTHESIS INHIBITORS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  5. GLOBAL RNA SYNTHESIS INHIBITORS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  6. GLOBAL MYCOLIC ACID INHIBITORS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  7. GLOBAL ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  8. GLOBAL CEPHALOSPORIN ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  9. GLOBAL PENICILLIN ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  10. GLOBAL FLUOROQUINOLONE ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  11. GLOBAL MACROLIDES ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  12. GLOBAL CARBAPENEM ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  13. GLOBAL AMINOGLYCOSIDES ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  14. GLOBAL SULFONAMIDES ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  15. GLOBAL OTHERS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  16. GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  17. GLOBAL BROAD-SPECTRUM ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  18. GLOBAL NARROW-SPECTRUM ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  19. GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  20. GLOBAL ORAL ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  21. GLOBAL INTRAVENOUS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  22. GLOBAL OTHERS ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  23. GLOBAL ANTIBIOTICS MARKET, BY REGION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  24. NORTH AMERICA ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  25. NORTH AMERICA ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  26. NORTH AMERICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  27. NORTH AMERICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  28. U.S. ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  29. U.S. ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  30. U.S. ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  31. U.S. ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  32. CANADA ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  33. CANADA ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  34. CANADA ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  35. CANADA ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  36. MEXICO ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  37. MEXICO ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  38. MEXICO ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  39. MEXICO ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  40. EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  41. EUROPE ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  42. EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  43. EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  44. U.S. ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  45. U.S. ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  46. U.S. ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  47. U.S. ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  48. CANADA ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  49. CANADA ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  50. CANADA ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  51. CANADA ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  52. MEXICO ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  53. MEXICO ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  54. MEXICO ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  55. MEXICO ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  56. GERMANY ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  57. GERMANY ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  58. GERMANY ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  59. GERMANY ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  60. FRANCE ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  61. FRANCE ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  62. FRANCE ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  63. FRANCE ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  64. U.K. ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  65. U.K. ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  66. U.K. ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  67. U.K. ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  68. ITALY ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  69. ITALY ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  70. ITALY ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  71. ITALY ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  72. SPAIN ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  73. SPAIN ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  74. SPAIN ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  75. SPAIN ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  76. ASIA PACIFIC ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  77. ASIA PACIFIC ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  78. ASIA PACIFIC ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  79. ASIA PACIFIC ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  80. JAPAN ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  81. JAPAN ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  82. JAPAN ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  83. JAPAN ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  84. CHINA ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  85. CHINA ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  86. CHINA ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  87. CHINA ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  88. INDIA ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  89. INDIA ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  90. INDIA ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  91. INDIA ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  92. SOUTH AMERICA ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  93. SOUTH AMERICA ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  94. SOUTH AMERICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  95. SOUTH AMERICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  96. BRAZIL ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  97. BRAZIL ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  98. BRAZIL ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  99. BRAZIL ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  100. MIDDLE EAST AND AFRICA ANTIBIOTICS MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  101. MIDDLE EAST AND AFRICA ANTIBIOTICS MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  102. MIDDLE EAST AND AFRICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  103. MIDDLE EAST AND AFRICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  104. BRAZIL ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  105. BRAZIL ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  106. BRAZIL ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  107. BRAZIL ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  108. UAE ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  109. UAE ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  110. UAE ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  111. UAE ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  112. SOUTH AFRICA ANTIBIOTICS  MARKET, BY ACTION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  113. SOUTH AFRICA ANTIBIOTICS  MARKET, BY SPECTRUM OF ACTIVITY, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  114. SOUTH AFRICA ANTIBIOTICS  MARKET, BY ROUTE OF ADMINISTRATION, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)
  115. SOUTH AFRICA ANTIBIOTICS  MARKET, BY DRUG CLASS, 2016–2026 REVENUE (USD MILLION), VOLUME (THOUSAND UNITS), PRICE (USD/THOUSAND UNITS)

LIST OF FIGURES

  1. GLOBAL ANTIBIOTICS MARKET SEGMENTATION
  2. ANTIBIOTICS MARKET: RESEARCH METHODOLOGY
  3. MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  4. MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  5. DATA TRIANGULATION
  6. PORTER’S FIVE FORCES ANALYSIS
  7. VALUE CHAIN ANALYSIS
  8. GLOBAL ANTIBIOTICS MARKET ATTRACTIVENESS ANALYSIS BY DRUG CLASS
  9. GLOBAL ANTIBIOTICS MARKET ATTRACTIVENESS ANALYSIS BY COMPONENT
  10. GLOBAL ANTIBIOTICS MARKET ATTRACTIVENESS ANALYSIS BY SPECTRUM OF ACTIVITY
  11. GLOBAL ANTIBIOTICS MARKET ATTRACTIVENESS ANALYSIS BY ROUTE OF ADMINISTRATION
  12. GLOBAL ANTIBIOTICS MARKET ATTRACTIVENESS ANALYSIS BY REGION
  13. GLOBAL ANTIBIOTICS MARKET: DYNAMICS
  14. GLOBAL ANTIBIOTICS MARKET SHARE BY DRUG CLASS (2018 & 2026)
  15. GLOBAL ANTIBIOTICS MARKET SHARE BY COMPONENT (2018 & 2026)
  16. GLOBAL ANTIBIOTICS MARKET SHARE BY SPECTRUM OF ACTIVITY (2018 & 2026)
  17. GLOBAL ANTIBIOTICS MARKET SHARE BY ROUTE OF ADMINISTRATION (2018 & 2026)
  18. GLOBAL ANTIBIOTICS MARKET SHARE BY REGION (2018 & 2026)
  19. GLOBAL ANTIBIOTICS MARKET SHARE BY COMPANY (2018)

EXTRA CUSTOMIZATION

  • NORTH AMERICA
    • U.S.
    • CANADA
    • MEXICO
  • EUROPE
    • GERMANY
    • FRANCE
    • SWEDEN
    • NETHERLANDS
    • U.K.
    • ITALY
    • SPAIN
    • TURKEY
    • SWITZERLAND
    • BELGIUM
    • REST OF EUROPE
  • ASIA-PACIFIC
    • JAPAN
    • CHINA
    • INDIA
    • SOUTH KOREA
    • AUSTRALIA
    • SINGAPORE
    • MALAYSIA
    • THAILAND
    • INDONESIA
    • PHILIPPINES
    • REST OF ASIA PACIFIC
  • SOUTH AMERICA
    • BRAZIL
    • ARGENTINA
    • COLOMBIA
    • REST OF SOUTH AMERICA
  • MIDDLE EAST AND AFRICA
    • SAUDI ARABIA
    • UAE
    • EGYPT
    • NIGERIA
    • SOUTH AFRICA
    • REST OF  MIDDLE EAST AND AFRICA


Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \
   Payment Mode



For More Information

   For More Information

If you have any query? Please contact us

sales@fiormarkets.com
+1-201-465-4211


Copyright © 2020 Fior Market Research LLP, All Rights Reserved.